Analyst Ratings for [ATAI] ATA Inc. - ADS, each representing two common shares

11/18/24	Reiterated	Buy	X
ATAI atai Life Sciences N.V. H.C. Wainwright
$15 $10
4/3/24	Upgrades	Hold Buy	X
ATAI atai Life Sciences N.V. Maxim Group
$6
11/1/22	Initiated	Buy	X
ATAI atai Life Sciences N.V. Loop Capital
$18
11/30/21	Initiated	Buy	X
ATAI atai Life Sciences N.V. Maxim Group
$25
11/11/21	Initiated	Buy	X
ATAI atai Life Sciences N.V. ROTH Capital
$32
10/18/21	Initiated	Buy	X
ATAI atai Life Sciences N.V. H.C. Wainwright
$40
7/13/21	Initiated	Buy	X
ATAI ATA Inc Berenberg
$35
7/13/21	Initiated	Buy	X
ATAI ATA Inc Canaccord Genuity
$28
7/13/21	Initiated	Buy	X
ATAI ATA Inc Cantor Fitzgerald
$45
7/13/21	Initiated	Buy	X
ATAI ATA Inc Citigroup
$26
7/13/21	Initiated	Outperform	X
ATAI ATA Inc Cowen
7/13/21	Initiated	Outperform	X
ATAI ATA Inc Credit Suisse
$25
7/13/21	Initiated	Sector Perform	X
ATAI ATA Inc RBC Capital Mkts
$19

ATAI ATA Inc. - ADS, each representing two common shares

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

ATA Inc. (ATA) is a provider of computer-based testing services in China. The Company offers services for the creation and delivery of computer-based tests utilizing its test delivery platform, testing technologies and testing services in China. Its computer-based testing services are used for licensure and certification tests in various industries, including information technology (IT) services, banking, securities, teaching and insurance. The Company's computer-based testing services clients include professional associations, Chinese governmental agencies and state-owned enterprises. As of March 31, 2016, the Company's test center network included approximately 3,035 test centers located throughout China. Its network allows its clients to administer computer-based and paper-based tests. The Company has delivered approximately 88.1 million tests, including approximately 11.8 million free tests for business development purposes.